$SRRK

Scholar Rock Holding Corp

Scholar Rock is a biopharmaceutical company developing therapies for children and adults with spinal muscular atrophy and other rare, severe neuromuscular diseases. It uses a proprietary platform to discover monoclonal antibodies that selectively target inactive precursor forms of growth factors. Its lead investigational product, apitegromab, is an anti-myostatin antibody in development for SMA and facioscapulohumeral muscular dystrophy, with both intravenous and subcutaneous formulations. Its clinical-stage pipeline also includes SRK-439, a subcutaneous anti-myostatin antibody for rare neuromuscular diseases. Scholar Rock’s early-stage programs include candidates for solid tumors, fibrotic diseases and iron-restricted anemias. The company is seeking partners for these additional programs. It is also developing a commercial organization to support apitegromab, with a U.S. customer-facing team and a European build-out starting with Germany. Scholar Rock is headquartered in Cambridge, Massachusetts.

AlphAI earnings readQ3 FY2026 · NOV 10Scholar Rock reports Q3 2026 net loss of $107.2 million as first ISEMBYLD product revenue of $570 thousand is recordedVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
1
$12.0M
—
AKKARAJU SRINIVAS
0%
See all $SRRK insider activity →

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

SRRK sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SRRK (Scholar Rock Holding Corp). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.

Recent SRRK coverage spans earnings, financial news and mergers & acquisitions.

In the last 30 days, SRRK insiders filed 6 SEC Form 4 transactions — 6 purchases ($12.0M) and no sales. The most active reporter was AKKARAJU SRINIVAS with 6 filings.

What's driving SRRK

AlphAI scores every news story that mentions SRRK with an AI model for sentiment and relevance, and aggregates insider trades from Scholar Rock Holding Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SRRK

Score

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.

$SRRKHighEarnings

Scholar Rock Reports Third Quarter 2026 Financial Results and Recent

Scholar Rock Holding Corp (SRRK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights • U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following Se

Tuesday’s insider trading: Scholar Rock director buys $12 million

Scholar Rock (SRRK) director acquired $12M in shares at $41.31-$41.82, indirectly via investment entities. Stride (LRN) director bought $12.18M in shares at $78.44-$79.84. Data I/O (DAIO) 10% owner bought $999,996 in stock and $3M in convertible debentures. Nuveen (NUV) trustee purchased $300,394 in shares. Talos (TALO) 10% owner sold $45.82M in shares at $18.20-$18.51. Snowflake (SNOW) director sold $16.95M in shares at $339.08. Goldman Sachs (GS) CEO sold $10.93M in shares at $910.46-$912.11.

Truist reiterates Buy on Scholar Rock stock, cites uptake potential

Truist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK), citing potential uptake of its Isembyld treatment for spinal muscular atrophy. Analysts expect 50-60% of patients to use the drug within five years, with key opinion leaders validating trial results and noting functional improvements. The stock trades at $41.14, with a Strong Buy consensus and price targets ranging from $58 to $84.

Related tickers